[A13-20] Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Last updated 01.08.2013

Project no.:

Commission awarded on 30.04.2013 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Head and nerves


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Ocriplasmin: indication of major added benefit for certain patients

Improved visual acuity and fewer operations in patients with mild symptoms

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.